Eledon Pharmaceuticals (ELDN) Equity Average (2014 - 2026)

Eledon Pharmaceuticals has reported Equity Average for 13 years, with the latest figure at $62.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 3.72% year-over-year to $62.9 million; the trailing twelve-month figure through Mar 2026 stood at $62.9 million (up 3.72% YoY), and the FY2025 full-year result was $71.8 million, up 928.16% from the prior year.
• Equity Average for Q1 2026 stood at $62.9 million, up from $58.2 million in the prior quarter.
• The five-year high for Equity Average was $160.2 million in Q1 2022, with the low at -$67.3 million in Q2 2024.
• Historically, Equity Average has averaged $50.3 million across 5 years, with a median of $54.6 million in 2025.
• The largest YoY upside for Equity Average was 742.49% in 2024 against a maximum downside of 220.62% in 2024.
• Eledon Pharmaceuticals' Equity Average stood at $82.4 million in 2022, then plunged by 107.82% to -$6.4 million in 2023, then jumped by 742.49% to $41.4 million in 2024, then surged by 40.62% to $58.2 million in 2025, then gained by 8.08% to $62.9 million in 2026.
• The last three Equity Average figures came in at $62.9 million (Q1 2026), $58.2 million (Q4 2025), and $42.8 million (Q3 2025), per Business Quant data.